Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.500 -0.330 (-3.36%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

October 05, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

October 03, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs ↗

September 27, 2023

U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...

Via Benzinga

What 8 Analyst Ratings Have To Say About Vir Biotechnology ↗

September 08, 2023

Via Benzinga

Is Vir Biotechnology Stock a Buy? ↗

August 11, 2023

The biotech is out to prove that it isn't just a "pandemic stock."

Via The Motley Fool

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Where Vir Biotechnology Stands With Analysts ↗

July 21, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Why Vir Biotechnology Stock Is Plunging Today? ↗

July 20, 2023

Vir Biotechnology Inc (NASDAQ: VIR) shares are tumbling after the company released data from the Phase 2 PENINSULA evaluating VIR-2482 to prevent

Via Benzinga

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

September 20, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades ↗

September 08, 2023

BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023 ↗

September 08, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 08, 2023

Friday's session saw 225 companies set new 52-week lows.

Via Benzinga

Planet Labs PBC, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 08, 2023

U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 07, 2023

On Thursday, 283 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 05, 2023

On Tuesday morning, 164 companies achieved new lows for the year.

Via Benzinga

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

August 29, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 03, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

July 26, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

Microsoft, Snap, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

July 26, 2023

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. Snap Inc. (NYSE: SNAP) shares tumbled 18.6% to $10.18 in...

Via Benzinga

Crude Oil Edges Higher; American Airlines Raises Profit Outlook ↗

July 20, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 250 points on Thursday. The Dow traded up 0.60% to 35,270.02 while the NASDAQ fell 1.89% to 14,086.02....

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

July 20, 2023

During Thursday's session, 40 stocks hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 20, 2023

Via Benzinga

Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

July 20, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.

Via Benzinga

Dow On Track For 9 Straight After Johnson & Johnson Earnings ↗

July 20, 2023

The Dow Jones Industrial Average is looking to extend its win streak, last seen up 250 points as it paces for its ninth consecutive win.

Via Talk Markets

Dow Surges 300 Points; Johnson & Johnson Posts Upbeat Earnings ↗

July 20, 2023

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite declining over 1% on Thursday. The Dow traded up 0.87% to 35,365.00 while the NASDAQ fell 1.11% to 14,198.86. The S&P 500,...

Via Benzinga

Why Shares of Vir Biotechnology Are Plunging Thursday ↗

July 20, 2023

The company had disappointing trial news for one of its lead therapies.

Via The Motley Fool

Nasdaq Down 50 Points; Tesla Earnings Beat Expectations ↗

July 20, 2023

U.S. stocks traded mixed this morning, with the Dow Jones gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.40% to 35,202.41 while the NASDAQ fell 0.35% to...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 20, 2023

Via Benzinga

Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness

July 20, 2023

From Vir Biotechnology, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.